Impacting HCC Outcomes with Multimodal Therapy: The Importance of Interdisciplinary Management

Impacting HCC Outcomes with Multimodal Therapy: The Importance of Interdisciplinary Management

On-Demand Webcast

Ripal Gandhi, MD, FSIR, FSVM
Miami Cardiac & Vascular Institute
Associate Clinical Professor
Florida International University, Herbert Wertheim College of Medicine
Associate Clinical Professor, University of South Florida College of Medicine
Miami, Florida

Constantino Pena, MD, FSIR
Medical Director, Vascular Imaging
Interventional Radiology
Miami Cardiac & Vascular Institute
Voluntary Clinical Assistant Professor, Radiology
Florida International University, Herbert Wertheim College of Medicine
Affiliate Assistant Professor, Radiology
University of South Florida College of Medicine
Miami, Florida

Edward Kim, MD, FSIR
Associate Professor of Radiology and Surgery
Director, Interventional Oncology
Mount Sinai Health System
New York, NY

Gennaro Selvaggi, MD, FACS
Associate Professor of Clinical Surgery
Liver and GI Transplant Division
Miami Transplant Institute
Miami, Florida

Richard Kim, MD
Associate Professor
Section Chief of GI Oncology
Department of Gastrointestinal Oncology
Moffitt Cancer Center
Tampa, Florida


Provided by North American Center for Continuing Medical Education, LLC, an HMP Company.

For questions regarding this educational activity, please call 609-371-1137 or email


This activity is designed for Interventional radiologists, oncologists, surgeons, and other members of the multidisciplinary oncology care team involved in the management of HCC.


After participating in this activity, participants should be better able to:

  • Identify challenges to optimal screening, diagnostic, and staging procedures and the role that interdisciplinary teams play in the prompt assessment and treatment of HCC
  • Discuss current guideline recommendations concerning resection, transplant, and the use of locoregional and systemic therapies across disease stages in patients with HCC
  • Describe the pharmacological properties of novel and emerging systemic therapies for HCC, including their mechanisms of action, efficacy and safety data, and indications
  • Apply strategies for multidisciplinary care that incorporate a spectrum of treatment modalities and clinical specialties to the construction of real-world treatment plans for patients with HCC
claiming crediT

This on-demand webcast is available with audio.

In order to be eligible for documentation of credit, participants must attend the full webcast, complete the post-test with a score of 75% or better, and complete the evaluation form. After successful completion of the post-test and evaluation form online at, participants may immediately print their documentation of credit.
Release Date: November 12, 2019
Expiration Date: November 12, 2020
Estimated time to complete: 1 hour

There is no fee associated with this activity.

For questions regarding this educational activity, please call 609-371-1137.


NACCME would like to thank the followingcompanies who has/have supported the "Impacting HCC Outcomes with Multimodal Therapy: The Importance of Interdisciplinary Management" through educational grants and/or in-kind support: Bayer HealthCare Pharmaceuticals, Eisai, Inc., and Merck.


    In support of improving patient care, NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


NACCME designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This continuing nursing education activity awards 1.00 contact hours.

Provider approved by the California Board of Registered Nursing, Provider #13255 for 1.00 contact hours.


NACCME has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 credit.
PAs should only claim credit commensurate with the extent of their participation.


This continuing medical education activity may include device or medicine brand names for participant clarity purposes only, due to the presence of different branded versions of the same product. No product promotion or recommendation should be inferred.


This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the European Medicines Agency (EMA) of the European Union or the Food and Drug Administration (FDA) of the United States. Participants are strongly encouraged to consult approved product labeling for any drug or device mentioned in this activity before use. The opinions expressed during this activity are the opinions of the respective authors, presenters or moderators and do not necessarily reflect the opinions of NACCME.


The material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.

Neither NACCME nor any of its subsidiaries or affiliates is affiliated with, or formally endorsed by a medical society.

The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME or HMP. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.


NACCME, LLC is an independent provider(s) of continuing medical education. NACCME, LLC has no proprietary or financial interest in medical or healthcare products over which the FDA (USA) or EMA (EU) has regulatory authority.

NACCME, LLC assures that all educational materials are reviewed to ensure for the absence of commercial bias, fair balance, scientific objectivity, and levels of evidence. The educational activity will not be influenced by commercial organizations and will not conflict with any other scheduled educational activities.

According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

Clinical Reviewers

Interventional Radiologist
Miami Cardiac & Vascular Institute
South Miami Heart Center
Miami, Florida

Planning Committee

The planning committee comprises Constantino Pena, MD; Ripal Gandhi, MD; Edward Kim, MD; Gennaro Selvaggi, MD, Richard Kim, MD, Adam Geronemus, MD; and MaryEllen Fama, Jennifer Ilcyn, Joanna Tong, Colleen Waters, and Chris Bolwell, NACCME.


The faculty has reported the following:

Ripal Gandhi, MD: Consultant – Medtronic, Bard; Speakers’ Bureau – Boston Scientific; Other Financial or Material Support – Sirtex Proctor

Adam Geronemus, MD has nothing to disclose.

Edward Kim, MD: Advisory Board and Consultant–Bristol Myers Squibb, BTG, BSC; Advisory Board–Roche Pharmaceuticals, Accurate Medical (Guerbet)

Gennaro Selvaggi, MD has nothing to disclose.

Richard Kim, MD: Consultant–BMS, Bayer; Advisory Board–BMS, Bayer, Lilly; Honorarium/Speakers’ Bureau–Lilly; Grant/Research Support–Eisai, BMS, Bayer

Constantino Peña, MD: Speakers’ Bureau – Penumbra, Boston Scientific, Cook Medical, CR Bard BD, Abbott Vascular

Ms. Fama, Ms. Ilcyn, Ms. Tong, Ms. Waters, and Mr. Bolwell have disclosed no relevant financial relationships with any commercial interests.

NACCME requires faculty to inform participants whenever off-label/unapproved uses of drugs and/or devices are discussed in their presentations. The faculty has disclosed that there were be no off-label discussion. 


North American Center for Continuing Medical Education (NACCME) complies with the legal requirements of the Americans with Disabilities Act and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please call 609-371-1137.


NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint providers. NACCME and our joint providers will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting purposes to the appropriate accrediting agency. NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2019 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education.